Cannabidiol (Epidyolex®) for severe behavioral manifestations in patients with tuberous sclerosis complex, mucopolysaccharidosis type III and fragile X syndrome: protocol for a series of randomized, placebo-controlled N-of-1 trials.

Published in:

BMC Psychiatry, 2024, v. 24, n. 1, p. 1, doi. 10.1186/s12888-023-05422-3

By:

• Müller, A. R.;
• den Hollander, B.;
• van de Ven, P. M.;
• Roes, K. C. B.;
• Geertjens, L.;
• Bruining, H.;
• van Karnebeek, C. D. M.;
• Jansen, F. E.;
• de Wit, M. C. Y.;
• ten Hoopen, L. W.;
• Rietman, A. B.;
• Dierckx, B.;
• Wijburg, F. A.;
• Boot, E.;
• Brands, M. M. G.;
• van Eeghen, A. M.

Publication type:

Article